Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for CKD–MBD with Low Bone Mineral Density
ChiCTR2200056463Phase 4Not yet recruiting
- Sponsor
- Tianjin Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in chronic kidney disease-mineral and bone disorder (CKD-MBD), low bone mineral density and osteoporosis, sponsored by Tianjin Hospital. Primary endpoints: Serum calcium (Ca), Serum phosphorus (P) and 4 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
chronic kidney disease-mineral and bone disorder (CKD-MBD)low bone mineral densityosteoporosis
Beyond the preview
Go deeper on ChiCTR2200056463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056463.